This is the classic website, which will be retired eventually. Please visit the modernized ClinicalTrials.gov instead.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT06036368
Recruitment Status : Not yet recruiting
First Posted : September 13, 2023
Last Update Posted : September 13, 2023
Sponsor:
Information provided by (Responsible Party):
Stimvia s.r.o.

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
This is a 6-week exploratory clinical study, designed to test whether treatment with peroneal electrical trans-cutaneous stimulation can have a beneficial effects on symptoms associated with Parkinson's diseases and essential tremor.

Condition or disease Intervention/treatment Phase
Parkinson's Disease Essential Tremor Device: Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®) Not Applicable

Detailed Description:
This is a 6-week, open-label, single site clinical study designed to test whether treatment with peroneal electrical trans-cutaneous stimulation (eTNM) can have a beneficial effects on symptoms associated with Parkinson's diseases (PD) and essential tremor (ET). Eligible patients will be treated with eTNM at home for 6 weeks. Primary endpoint in this study is tolerability and safety, secondary and exploratory endpoints are various scale designed to capture improvements in the most bothersome symptoms of PD or ET.
Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: 6-weeks, Open-label, Single-Site Study to Evaluate Safety, Tolerability and Efficacy of the Home-based Peroneal Electrical Transcutaneous NeuroModulation (Peroneal eTNM®) Treatment Via Nerve Stimulator URIS ITM in Treatment of Symptoms Related to Movement Disorders in Subjects With Parkinson's Disease (PD) and Essential Tremor (ET)
Estimated Study Start Date : September 15, 2023
Estimated Primary Completion Date : March 31, 2024
Estimated Study Completion Date : June 30, 2024

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Peroneal eTNM arm
All patients will receive treatment with peroneal eTNM
 Device: Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
This is a non-invasive intervention, which utilizes direct trancutaneous, electrical stimulation of the peroneal nerve


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Safety and tolerability [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Incidence of treatment emergent adverse events


Secondary Outcome Measures :
  1. Efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Change in Patient Global Impression of Improvement scale (Scores 1-7, lower number = better)


Other Outcome Measures:
  1. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    The Movement Disorders Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS) score (both total score and subscores) (applicable only for subjects with PD)(0-260, lower score = better)

  2. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Essential tremor rating assessment scale (TETRAS) score (applicable only for subjects with ET, 0-64, lower scores = better))

  3. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Bradykinesis and rigidity measured by Five Times Sit to Stand Test (FTSTS) (applicable only for subjects with PD, time in seconds, lower = better))

  4. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Bradykinesis and rigidity measured objectively using the 10 meter Walking Speed Test (WST) (time in seconds, lower = better)(applicable only for subjects with PD)

  5. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Effect on patient's daily activities measured by Bain and Findley Activities of Daily Living (BF-ADL) (25-100, lower score = better)

  6. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Degree of disability measured by modified Rankin Scale (mRS) (0-6, lower score= better)

  7. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Quality of life measured by European Quality of Life-5 Dimensions questionnaire (EQ-5D-5L)(0.532-1.000, higher score = better)

  8. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Disease-specific quality of life measured by Parkinson's Disease Questionnaire (PDQ -39)(0-100, lower score = better)

  9. Exploratory efficacy [ Time Frame: Baseline to end of treatment at 6 weeks ]
    Patient's satisfaction using Treatment Satisfaction Visual Analog scale (TS-VAS)(0-100, higher score = better)


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • 18 years of age
  • Competent and willing to provide written, informed consent to participate in the study
  • Stable dose of any chronic medications, if applicable, for 30 days prior to study entry
  • Willing to comply with study protocol requirements
  • Subject agrees not to participate in another study from 30 days prior the screening visit until the final study visit
  • For subjects with PD:

Bradykinesia in "on" period based on clinical assessment Rigidity in "on" period based on clinical assessment Hand/arm exhibiting tremor (resting and/or intentional and/or postural) ≥ grade 1 as assessed by the MDS-UPDRS tremor score in "on" period

• For subjects with ET: Visible hand/arm and/or foot/leg tremor (resting and/or intentional and/or postural) ≥ grade 1 as assessed by the TETRAS

Exclusion Criteria:

  • Implanted electrical medical device, such as a pacemaker, defibrillator, or deep brain stimulator
  • Suspected or diagnosed epilepsy or other seizure disorder
  • Severe degree of disability or dependence in daily activities >grade 3 as measured by modified Rankin Scale (mRS)
  • Presence of clinical signs or diagnosis of dementia
  • Swollen, infected, inflamed areas, or skin eruptions, open wounds, or cancerous lesions of skin at stimulation site
  • Presence of clinical signs of peripheral neuropathy on lower limbs
  • Presence of chorea and/or dyskinesia
  • Clinical symptoms or diagnosis of major depressive disorder
  • Presence of any other neurodegenerative disease. These may include multisystem atrophy, progressive supranuclear palsy, dementia with Lewy bodies, and Alzheimer's disease.
  • Botulinum toxin injection within 6 months prior to study enrollment
  • Participation in another interventional clinical trial in the last 30 days, which may confound the results of this study, unless approved by the Sponsor
  • Subject is breastfeeding, pregnant, intends to become pregnant during the study, or of childbearing potential, sexually active and not practicing a highly reliable method of birth control (these are methods with a failure quotient of <1% year such as hormonal implants, injectable contraceptives, oral contraceptives of combination type, intra-uterine pessaries restricted to hormone contraceptive coil, sexual abstinence or vasectomy of the partner). The pregnancy test in urine at both Visits 1 and 2 needs to be negative in women of childbearing potential.
  • Subjects unable to communicate effectively with the investigator and staff
  • Life expectancy less than 6 months
  • Subject with active malignant disease
  • Subject with alcohol (more than 100 mg ethanol per day) or drug abuse during the recruitment and during the trial course
  • Subject who, in the opinion of the physician, may interfere with optimal participation in the clinical trial or may pose a risk to the subject
  • Characteristics indicating a poor understanding of the study or characteristics that indicate the subject may have poor compliance with the study protocol
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT06036368


Contacts
Layout table for location contacts
Contact: Roman V Dvorak, MD PhD +420 734 577 837 dvorak@stimvia.com
Contact: Lukas Doskocil +420 776 721 127 doskocil@stimvia.com

Locations
Layout table for location information
Czechia
Cerebrovaskulární poradna s.r.o.
Ostrava, Czechia, 70200
Contact: David Skoloudik, MD, PhD    +420 739 782 970    skoloudik@email.cz   
Sponsors and Collaborators
Stimvia s.r.o.
Investigators
Layout table for investigator information
Principal Investigator: David Skoloudik, MD, PhD Cerebrovaskulární poradna s.r.o., Ostrava
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Stimvia s.r.o.
ClinicalTrials.gov Identifier: NCT06036368    
Other Study ID Numbers: TS004-PD
First Posted: September 13, 2023    Key Record Dates
Last Update Posted: September 13, 2023
Last Verified: September 2023
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: No
Keywords provided by Stimvia s.r.o.:
Parkinson's Disease (PD) and Essential Tremor (ET)
Peroneal Electrical Transcutaneous NeuroModulation
Additional relevant MeSH terms:
Layout table for MeSH terms
Parkinson Disease
Tremor
Essential Tremor
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
 Nervous System Diseases
Movement Disorders
Synucleinopathies
Neurodegenerative Diseases
Dyskinesias
Neurologic Manifestations